Skip to main content
Erschienen in: Journal of Nephrology 2/2019

01.04.2019 | Original Article

Sustained low-efficiency dialysis for metformin-associated lactic acidosis in patients with acute kidney injury

verfasst von: Paolo Greco, Giuseppe Regolisti, Umberto Maggiore, Elena Ferioli, Filippo Fani, Carlo Locatelli, Elisabetta Parenti, Caterina Maccari, Ilaria Gandolfini, Enrico Fiaccadori

Erschienen in: Journal of Nephrology | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

The choice of the specific modality and treatment duration of renal replacement therapy (RRT) to adopt in metformin-associated lactic acidosis (MALA) is still debated. We aimed to verify if sustained low-efficiency dialysis (SLED) is a rational choice in patients with MALA and acute kidney injury (AKI).

Methods

We collected serial serum metformin measurements, clinical parameters, and outcome data in ten consecutive patients (mean age 77 years [range 58–88], 5 males) admitted to our renal intensive care unit for suspected MALA associated with AKI and hemodynamic instability. Patients underwent a 16-h SLED session performed with either conventional dialysis machines or machines for continuous RRT (CRRT). A 2-compartment open-infusion pharmacokinetic model with first-order elimination was fitted to each subject’s serum concentration–time data to model post-SLED rebound and predict the need for further treatments.

Results

Two patients died within 24 h after SLED start. Three patients needed one further dialysis session. Surviving patients (n = 8) were dialysis-free at discharge. Metformin levels were in the toxic range at baseline (median [range] 32.5 mg/l [13.6–75.6]) and decreased rapidly by the end of SLED (8.1 mg/l [4.5–15.8], p < 0.001 vs. baseline), without differences according to the dialysis machine used (p = 0.84). We observed a slight 4-h post-SLED rebound (9.7 mg/l [3.5–22.0]), which could be predicted by our pharmacokinetic model. Accordingly, we predicted that the majority of patients would need one additional dialysis session performed the following day to restore safe metformin levels.

Conclusions

A 16-h SLED session, performed with either conventional dialysis machines or CRRT machines, allows effective metformin removal in patients with MALA and AKI. However, due to possible post-SLED rebound in serum metformin levels, one additional dialysis treatment is required the following day in the majority of patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al (2015) Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38:140–149CrossRefPubMed Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al (2015) Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38:140–149CrossRefPubMed
2.
Zurück zum Zitat Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA et al (2016) Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm. 2016 Executive summary. Endocr Pract 22:84–113CrossRefPubMed Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA et al (2016) Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm. 2016 Executive summary. Endocr Pract 22:84–113CrossRefPubMed
3.
Zurück zum Zitat Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589CrossRef Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589CrossRef
4.
Zurück zum Zitat Lalau JD, Arnouts P, Sharif A, De Broe ME (2015) Metformin and other antidiabetic agents in renal failure patients. Kidney Int 87:308–322CrossRefPubMed Lalau JD, Arnouts P, Sharif A, De Broe ME (2015) Metformin and other antidiabetic agents in renal failure patients. Kidney Int 87:308–322CrossRefPubMed
5.
Zurück zum Zitat Lalau JD, Kajbaf F, Protti A, Christensen MM, De Broe ME, Wiernsperger N (2017) Metformin-associated lactic acidosis (MALA): moving towards a new paradigm. Diabetes Obes Metab 19:1502–1512CrossRefPubMed Lalau JD, Kajbaf F, Protti A, Christensen MM, De Broe ME, Wiernsperger N (2017) Metformin-associated lactic acidosis (MALA): moving towards a new paradigm. Diabetes Obes Metab 19:1502–1512CrossRefPubMed
7.
Zurück zum Zitat Calello D, Liu KD, Wiegand TJ, Roberts DM, Lavergne V, Gosselin S et al (2015) Extracorporeal treatment for metformin poisoning: systematic review and recommendations from the extracorporeal treatments in poisoning workgroup. Crit Care Med 43:1716–1730CrossRefPubMed Calello D, Liu KD, Wiegand TJ, Roberts DM, Lavergne V, Gosselin S et al (2015) Extracorporeal treatment for metformin poisoning: systematic review and recommendations from the extracorporeal treatments in poisoning workgroup. Crit Care Med 43:1716–1730CrossRefPubMed
8.
Zurück zum Zitat Palevsky PM, Liu KD, Brophy PD, Chawla LS, Parikh CR, Thakar CV et al (2013) KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. Am J Kidney Dis 61:649–672CrossRefPubMed Palevsky PM, Liu KD, Brophy PD, Chawla LS, Parikh CR, Thakar CV et al (2013) KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. Am J Kidney Dis 61:649–672CrossRefPubMed
9.
Zurück zum Zitat James M, Bouchard J, Ho J, Klarenbach S, LaFrance JP, Rigatto C et al (2013) Canadian Society of Nephrology commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. Am J Kidney Dis 61:673–685CrossRefPubMed James M, Bouchard J, Ho J, Klarenbach S, LaFrance JP, Rigatto C et al (2013) Canadian Society of Nephrology commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. Am J Kidney Dis 61:673–685CrossRefPubMed
10.
Zurück zum Zitat Fiaccadori E, Regolisti G, Cademartiri C, Cabassi A, Picetti E, Barbagallo M et al (2013) Efficacy and safety of a citrate-based protocol for sustained low-efficiency dialysis in AKI using standard dialysis equipment. Clin J Am Soc Nephrol 8:1670–1678CrossRefPubMedPubMedCentral Fiaccadori E, Regolisti G, Cademartiri C, Cabassi A, Picetti E, Barbagallo M et al (2013) Efficacy and safety of a citrate-based protocol for sustained low-efficiency dialysis in AKI using standard dialysis equipment. Clin J Am Soc Nephrol 8:1670–1678CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Regolisti G, Antoniotti R, Fani F, Greco P, Fiaccadori E (2017) Treatment of metformin intoxication complicated by lactic acidosis and acute kidney injury: the role of prolonged intermittent hemodialysis. Am J Kidney Dis 70:290–296CrossRefPubMed Regolisti G, Antoniotti R, Fani F, Greco P, Fiaccadori E (2017) Treatment of metformin intoxication complicated by lactic acidosis and acute kidney injury: the role of prolonged intermittent hemodialysis. Am J Kidney Dis 70:290–296CrossRefPubMed
12.
Zurück zum Zitat Frid A, Sterner GN, Löndahl M, Wiklander C, Cato A, Vinge E et al (2010) Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function: clinical recommendations. Diabetes Care 33:1291–1293CrossRefPubMedPubMedCentral Frid A, Sterner GN, Löndahl M, Wiklander C, Cato A, Vinge E et al (2010) Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function: clinical recommendations. Diabetes Care 33:1291–1293CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat D’Argenio DZ, Schumitzky A (1997) Adapt II release 4, user’s guide. In: Biomedical simulations resource. University of Southern California, Los Angeles D’Argenio DZ, Schumitzky A (1997) Adapt II release 4, user’s guide. In: Biomedical simulations resource. University of Southern California, Los Angeles
14.
Zurück zum Zitat Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF (1981) Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 12:235–246CrossRefPubMedPubMedCentral Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF (1981) Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 12:235–246CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Madiraju AK, Erion DM, Rahimi Y, Zhang XM, Braddock DT, Albright RA et al (2014) Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510:542–546CrossRefPubMedPubMedCentral Madiraju AK, Erion DM, Rahimi Y, Zhang XM, Braddock DT, Albright RA et al (2014) Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510:542–546CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Luengo A, Sullivan LB, Heiden MG (2014) Understanding the complex-I-ty of metformin action: limiting mitochondrial respiration to improve cancer therapy. BMC Biol 12:82CrossRefPubMedPubMedCentral Luengo A, Sullivan LB, Heiden MG (2014) Understanding the complex-I-ty of metformin action: limiting mitochondrial respiration to improve cancer therapy. BMC Biol 12:82CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Boucaud-Maitre D, Ropers J, Porokhov B, Altman JJ, Bouanick B, Doucet J et al (2016) Lactic acidosis: relationship between metformin levels, lactate concentration and mortality. Diabet Med 33:1536–1543CrossRefPubMed Boucaud-Maitre D, Ropers J, Porokhov B, Altman JJ, Bouanick B, Doucet J et al (2016) Lactic acidosis: relationship between metformin levels, lactate concentration and mortality. Diabet Med 33:1536–1543CrossRefPubMed
18.
Zurück zum Zitat Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK et al (2011) Clinical pharmacokinetics of metformin. Clin Pharmacokinet 50:81–98CrossRefPubMed Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK et al (2011) Clinical pharmacokinetics of metformin. Clin Pharmacokinet 50:81–98CrossRefPubMed
19.
Zurück zum Zitat Guideline development group (2015) Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR < 45 ml/min). Nephrol Dial Transpl 30(Suppl2):ii1–i142CrossRef Guideline development group (2015) Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR < 45 ml/min). Nephrol Dial Transpl 30(Suppl2):ii1–i142CrossRef
20.
Zurück zum Zitat Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 84(3):1–150 Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 84(3):1–150
22.
Zurück zum Zitat Inzucchi SE, Lipska J, Mayo H, Bailey CJ, McGuire DK (2014) Metformin in patients with type 2 diabetes and kidney disease, a systematic review. JAMA 312:2668–2675CrossRefPubMedPubMedCentral Inzucchi SE, Lipska J, Mayo H, Bailey CJ, McGuire DK (2014) Metformin in patients with type 2 diabetes and kidney disease, a systematic review. JAMA 312:2668–2675CrossRefPubMedPubMedCentral
23.
24.
Zurück zum Zitat Lalau JD, Andrejak M, Morinière P, Coevoet B, Debussche X, Westeel PF et al (1989) Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination. Int Clin Pharmacol Ther Toxicol 27:285–288 Lalau JD, Andrejak M, Morinière P, Coevoet B, Debussche X, Westeel PF et al (1989) Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination. Int Clin Pharmacol Ther Toxicol 27:285–288
25.
Zurück zum Zitat Xie F, Ke AB, Bowers GD, Zamek-Glisczynski MJ (2015) Metformin’s intrinsic blood-to-plasma partition ratio (B/P): reconciling the perceived high in vivo B/P> 10 with the in vitro equilibrium value of unity. J Pharmacol Exp Ther 354:225–229CrossRefPubMed Xie F, Ke AB, Bowers GD, Zamek-Glisczynski MJ (2015) Metformin’s intrinsic blood-to-plasma partition ratio (B/P): reconciling the perceived high in vivo B/P> 10 with the in vitro equilibrium value of unity. J Pharmacol Exp Ther 354:225–229CrossRefPubMed
26.
Zurück zum Zitat Heaney D, Majid A, Junor B (1997) Bicarbonate haemodialysis as a treatment of metformin overdose. Nephrol Dial Transpl 12:1046–1047CrossRef Heaney D, Majid A, Junor B (1997) Bicarbonate haemodialysis as a treatment of metformin overdose. Nephrol Dial Transpl 12:1046–1047CrossRef
27.
Zurück zum Zitat Chalopin JM, Tanter Y, Besancenot JF, Cabanne JF, Rifle G (1984) Treatment of metformin-associated lactic acidosis with closed recirculation bicarbonate buffered hemodialysis. Arch Intern Med 144:203–205CrossRefPubMed Chalopin JM, Tanter Y, Besancenot JF, Cabanne JF, Rifle G (1984) Treatment of metformin-associated lactic acidosis with closed recirculation bicarbonate buffered hemodialysis. Arch Intern Med 144:203–205CrossRefPubMed
28.
Zurück zum Zitat Panzer U, Kluge S, Kreymann G, Wolf G (2004) Combination of intermittent haemodialysis and high-volume continuous haemofiltration for the treatment of severe metformin-induced lactic acidosis. Nephrol Dial Transpl 19:2157–2158CrossRef Panzer U, Kluge S, Kreymann G, Wolf G (2004) Combination of intermittent haemodialysis and high-volume continuous haemofiltration for the treatment of severe metformin-induced lactic acidosis. Nephrol Dial Transpl 19:2157–2158CrossRef
29.
Zurück zum Zitat Guo PY, Storsley LJ, Finkle SN (2006) Severe lactic acidosis treated with prolonged hemodialysis: recovery after massive overdoses of metformin. Semin Dial 19:80–83CrossRefPubMed Guo PY, Storsley LJ, Finkle SN (2006) Severe lactic acidosis treated with prolonged hemodialysis: recovery after massive overdoses of metformin. Semin Dial 19:80–83CrossRefPubMed
30.
Zurück zum Zitat Teutonico A, Libutti P, Lomonte C, Antonelli M, Casucci F, Basile C (2008) Treatment of metformin-associated lactic acidosis with sustained low-efficiency daily dialysis. NDT Plus 1:380–381PubMedPubMedCentral Teutonico A, Libutti P, Lomonte C, Antonelli M, Casucci F, Basile C (2008) Treatment of metformin-associated lactic acidosis with sustained low-efficiency daily dialysis. NDT Plus 1:380–381PubMedPubMedCentral
31.
Zurück zum Zitat Angioi A, Cabiddu F, Conti M, Pili G, Atzeni A, Matta V et al (2018) Metformin associated lactic acidosis: a case series of 28 patients treated with sustained low-efficiency dialysis (SLED) and long term follow-up. BMC Nephrol 19:77CrossRefPubMedPubMedCentral Angioi A, Cabiddu F, Conti M, Pili G, Atzeni A, Matta V et al (2018) Metformin associated lactic acidosis: a case series of 28 patients treated with sustained low-efficiency dialysis (SLED) and long term follow-up. BMC Nephrol 19:77CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Moioli A, Maresca B, Manzione A et al (2016) Metformin associated lactic acidosis (MALA): clinical profiling and management. J Nephrol 29:783–789CrossRefPubMed Moioli A, Maresca B, Manzione A et al (2016) Metformin associated lactic acidosis (MALA): clinical profiling and management. J Nephrol 29:783–789CrossRefPubMed
33.
Zurück zum Zitat Kajbaf F, Bennis Y, Hurtel-Lemaire AS, Andréjak M, Lalau JD (2016) Unexpectedly long half-life of metformin elimination in cases of metformin accumulation. Diabet Med 33:105–110CrossRefPubMed Kajbaf F, Bennis Y, Hurtel-Lemaire AS, Andréjak M, Lalau JD (2016) Unexpectedly long half-life of metformin elimination in cases of metformin accumulation. Diabet Med 33:105–110CrossRefPubMed
34.
Zurück zum Zitat Seidowsky A, Nseir S, Houdret N, Fourrier F (2009) Metformin-associated lactic acidosis: a prognostic and therapeutic study. Crit Care Med 37:2191–2196CrossRefPubMed Seidowsky A, Nseir S, Houdret N, Fourrier F (2009) Metformin-associated lactic acidosis: a prognostic and therapeutic study. Crit Care Med 37:2191–2196CrossRefPubMed
Metadaten
Titel
Sustained low-efficiency dialysis for metformin-associated lactic acidosis in patients with acute kidney injury
verfasst von
Paolo Greco
Giuseppe Regolisti
Umberto Maggiore
Elena Ferioli
Filippo Fani
Carlo Locatelli
Elisabetta Parenti
Caterina Maccari
Ilaria Gandolfini
Enrico Fiaccadori
Publikationsdatum
01.04.2019
Verlag
Springer International Publishing
Erschienen in
Journal of Nephrology / Ausgabe 2/2019
Print ISSN: 1121-8428
Elektronische ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-018-00562-2

Weitere Artikel der Ausgabe 2/2019

Journal of Nephrology 2/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.